Completed NA INTERVENTIONAL 1-arm NCT04993066

Clinical Evaluation to Assess the Safety and Efficacy of GentleMax Pro Plus

Clinical Evaluation to Assess the Safety and Efficacy of GentleMax Pro/ GentleMax Pro Plus

Sponsor: Candela Corporation

Conditions Acne Onychomycosis Pigmented Lesions Pseudofolliculitis Barbae Unwanted Hair Vascular Lesion Wrinkle

Updated 7 times since 2021 Last updated: Nov 13, 2023 Started: Nov 12, 2020 Primary completion: May 31, 2022 Completion: Apr 27, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on Acne and Onychomycosis, this trial is completed. The trial is conducted by Candela Corporation and has accumulated 7 data snapshots since 2020. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Dec 2023 — Jul 2024 [monthly]

Completed NA

Status: Active Not Recruiting → Completed
Mar 2023 — Dec 2023 [monthly]

Active Not Recruiting NA
Sep 2022 — Mar 2023 [monthly]

Active Not Recruiting NA

▶ Show 2 earlier versions

Apr 2022 — Sep 2022 [monthly]

Active Not Recruiting NA
Sep 2021 — Apr 2022 [monthly]

Active Not Recruiting NA

First recorded

Nov 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Candela Corporation

Data source: Candela Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Marlborough, United States